soul trial oral semaglutide cardiovascular outcomes 2024 2025 results Abstract 4351008: Comparing Cardiovascular Outcomes in New Users of Oral soul trial oral semaglutide cardiovascular

PMID 29767158

Compounded medications are prepared for an individual patient and are not FDA-approved

1 For full dosing instructions refer to Prescribing Information

5 By pairing medication with personalized nutrition and lasting behavior change, organizations can help members maintain progress while reducing reliance on lifelong medication

Clinically, qualifying for GLP-1 therapy typically requires meeting one of two conditions: a BMI of 30 kg/m or greater, or a BMI of 27 kg/m or greater combined with an obesity-related comorbidity such as type 2 diabetes or cardiovascular risk factors

Low Magnesium Can Deplete Glutathione Magnesium is essential for many of the enzymatic reactions within the cells, including those involved in the immune response